Cytosorbents (CTSO) Invested Capital (2010 - 2026)

Cytosorbents has reported Invested Capital for 17 years, with the latest figure at $8.8 million in Q1 2026.

• For the quarter ending Q1 2026, Invested Capital fell 39.22% year-over-year to $8.8 million; the trailing twelve-month figure through Mar 2026 stood at $8.8 million (down 39.22% YoY), and the FY2025 full-year result was $5.9 million, down 46.85% from the prior year.
• Invested Capital for Q1 2026 stood at $8.8 million, up from $5.9 million in the prior quarter.
• The five-year high for Invested Capital was $55.4 million in Q1 2022, with the low at $5.9 million in Q4 2025.
• Historically, Invested Capital has averaged $24.9 million across 5 years, with a median of $23.8 million in 2023.
• Annual changes were most pronounced in 2024 — Invested Capital plunged 61.06% — and 2025, when it jumped 79.48%.
• Cytosorbents' Invested Capital stood at $35.4 million in 2022, then slipped by 19.37% to $28.5 million in 2023, then tumbled by 61.06% to $11.1 million in 2024, then plunged by 46.85% to $5.9 million in 2025, then soared by 49.75% to $8.8 million in 2026.
• The last three Invested Capital figures came in at $8.8 million (Q1 2026), $5.9 million (Q4 2025), and $24.0 million (Q3 2025), per Business Quant data.